|
|
|
|
 |
SAN DIEGO--- Bio-Quant Adds Dr. Roberto Crea to the Board |
| Companies mentioned in this article: |
|
Bio-Quant |
|
| 10/6/2008 @ 7:10 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Bio-Quant, Inc. ("Bio-Quant") the largest biotech Contract Research Organization (CRO) in San Diego, announced today the addition of Dr. Roberto Crea, one of the scientific co-founders of Genetech, to the board of directors. Dr. Crea replaces Mr. John Ryan. We are very grateful for Mr. Ryan’s service over the past several years. This brings the number of board members to 5, of whom 2 are independent.
Dr. Crea has over 30 years of experience in the biotechnology field as a scientist, investor and entrepreneur. He is one of the scientific co-founders of Genetech, founder of Creative Bio Molecules, Inc. (1982), Creagen, Inc. (1992), CreAgri (1998), Bioren (2002) and ProtElix (2005). Creagen, Inc. was merged into Neurex in 1994, which was then sold to Elan Pharmaceuticals for over $700 million. Pfizer successfully acquired Bioren in 2005.
Dr. Crea received his Ph.D. in Biological Chemistry from University of Pavia, Italy. He was also an Associate Professor of DNA Chemical Synthesis at Leiden University in the Netherlands prior to moving to the US in 1977. Dr. Crea is the author of more than 25 international patents and has co-authored more than 50 scientific articles. He was also the recipient of the Rumbaugh Award for Scientific Contribution given by the Juvenile Diabetes Foundation for America.
“We are very pleased to have someone of Dr. Crea’s stature joining the board of Bio-Quant. Dr. Crea not only brings the highest level of scientific credibility to the company, but also is an extremely successful businessman and entrepreneur whose experience and skill brings a great deal to Bio-Quant,” said CEO Dr. Bassam Damaj.
About Bio-Quant, Inc.
Bio-Quant, Inc. is a profitable revenue-generating biotechnology pre-clinical contract research organization specializing in in vitro and in vivo pharmacology, PK and toxicology to support non-GLP pre-IND enabling studies in addition to vivarium housing services. The company is based in San Diego, California and has over 30 employees and 20,000 sq ft office and laboratory facilities. The company specializes in pre-clinical work in the areas of Inflammation, Oncology, and Immunology, PK and toxicology services.
More information is available at www.bio-quant.com |
| Tech People On the Move - California |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
SAN FRANCISCO--- FibroGen Appoints K. Peony Yu, M.D., Vice President, Clinical Development Posted 3:16 PM PST
SAN DIEGO--- NovaRx Appoints Industry Veteran as President and COO Posted 9:47 AM PST
SAN DIEGO--- Captura Group Names Renowned Hispanic Marketing Expert Felipe Korzenny, Ph.D. Senior Strategy Consultant Posted 9:22 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
SAN DIEGO--- DivX Announces Changes to Engineering Organization; Chief Technololgy Officer Resigns Posted 7:12 PM PST
MENLO PARK--- Caroline Loewy Joins Corcept as Chief Financial Officer Posted 7:32 AM PST
SAN FRANCISCO--- Neocase Software Appoints Julien Dahan Chief Executive Officer Posted 7:31 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
SACRAMENTO--- StrataScale Recruits Borland VP Robert Vincent to Be General Manager and CO Posted 8:42 AM PST
FOSTER CITY--- SciClone Pharmaceuticals Appoints Gary Titus as Chief Financial Officer Posted 8:28 AM PST
SAN DIEGO--- BrainCells Inc. Appoints David E. Thompson to Its Board of Directors Posted 8:23 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
AGOURA HILLS--- Symark International Appoints John Mutch as Chief Executive Officer Posted 8:32 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
